BACKGROUND: In HIV type-1-infected patients starting highly active antiretroviral therapy (HAART), the prognostic value of haemoglobin when starting HAART, and of changes in haemoglobin levels, are not well defined. METHODS: We combined data from 10 prospective studies of 12,100 previously untreated individuals (25% women). A total of 4,222 patients (35%) were anaemic: 131 patients (1.1%) had severe (<8.0 g/dl), 1,120 (9%) had moderate (male 8.0-<11.0 g/dl and female 8.0- < 10.0 g/dl) and 2,971 (25%) had mild (male 11.0- < 13.0 g/ dl and female 10.0- < 12.0 g/dl) anaemia. We separately analysed progression to AIDS or death from baseline and from 6 months using Weibull models, adjusting for CD4+ T-cell count, age, sex and other variables. RESULTS: During 48,420 person-years of follow-up 1,448 patients developed at least one AIDS event and 857 patients died. Anaemia at baseline was independently associated with higher mortality: the adjusted hazard ratio (95% confidence interval) for mild anaemia was 1.42 (1.17-1.73), for moderate anaemia 2.56 (2.07-3.18) and for severe anaemia 5.26 (3.55-7.81). Corresponding figures for progression to AIDS were 1.60 (1.37-1.86), 2.00 (1.66-2.40) and 2.24 (1.46-3.42). At 6 months the prevalence of anaemia declined to 26%. Baseline anaemia continued to predict mortality (and to a lesser extent progression to AIDS) in patients with normal haemoglobin or mild anaemia at 6 months. CONCLUSIONS: Anaemia at the start of HAART is an important factor for short- and long-term prognosis, including in patients whose haemoglobin levels improved or normalized during the first 6 months of HAART.
BACKGROUND: In HIV type-1-infectedpatients starting highly active antiretroviral therapy (HAART), the prognostic value of haemoglobin when starting HAART, and of changes in haemoglobin levels, are not well defined. METHODS: We combined data from 10 prospective studies of 12,100 previously untreated individuals (25% women). A total of 4,222 patients (35%) were anaemic: 131 patients (1.1%) had severe (<8.0 g/dl), 1,120 (9%) had moderate (male 8.0-<11.0 g/dl and female 8.0- < 10.0 g/dl) and 2,971 (25%) had mild (male 11.0- < 13.0 g/ dl and female 10.0- < 12.0 g/dl) anaemia. We separately analysed progression to AIDS or death from baseline and from 6 months using Weibull models, adjusting for CD4+ T-cell count, age, sex and other variables. RESULTS: During 48,420 person-years of follow-up 1,448 patients developed at least one AIDS event and 857 patients died. Anaemia at baseline was independently associated with higher mortality: the adjusted hazard ratio (95% confidence interval) for mild anaemia was 1.42 (1.17-1.73), for moderate anaemia 2.56 (2.07-3.18) and for severe anaemia 5.26 (3.55-7.81). Corresponding figures for progression to AIDS were 1.60 (1.37-1.86), 2.00 (1.66-2.40) and 2.24 (1.46-3.42). At 6 months the prevalence of anaemia declined to 26%. Baseline anaemia continued to predict mortality (and to a lesser extent progression to AIDS) in patients with normal haemoglobin or mild anaemia at 6 months. CONCLUSIONS:Anaemia at the start of HAART is an important factor for short- and long-term prognosis, including in patients whose haemoglobin levels improved or normalized during the first 6 months of HAART.
Authors: Jens D Lundgren; Amanda Mocroft; Jose M Gatell; Bruno Ledergerber; Antonella D'Arminio Monforte; Philippe Hermans; Frank-Detlef Goebel; Anders Blaxhult; Ole Kirk; Andrew N Phillips Journal: J Infect Dis Date: 2002-01-03 Impact factor: 5.226
Authors: Richard D Semba; Nina Shah; Robert S Klein; Kenneth H Mayer; Paula Schuman; David Vlahov Journal: Clin Infect Dis Date: 2001-12-04 Impact factor: 9.079
Authors: David K Lewis; Christopher J M Whitty; Amanda L Walsh; Henry Epino; Nynke R van den Broek; Elizabeth A Letsky; Clyton Munthali; Joshua M Mukiibi; Martin J Boeree Journal: Trans R Soc Trop Med Hyg Date: 2005-08 Impact factor: 2.184
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Paul A Volberding; Alexandra M Levine; Douglas Dieterich; Donna Mildvan; Ronald Mitsuyasu; Michael Saag Journal: Clin Infect Dis Date: 2004-04-27 Impact factor: 9.079
Authors: Margaret T May; Robert S Hogg; Amy C Justice; Bryan E Shepherd; Dominique Costagliola; Bruno Ledergerber; Rodolphe Thiébaut; M John Gill; Ole Kirk; Ard van Sighem; Michael S Saag; Gemma Navarro; Paz Sobrino-Vegas; Fiona Lampe; Suzanne Ingle; Jodie L Guest; Heidi M Crane; Antonella D'Arminio Monforte; Jörg J Vehreschild; Jonathan A C Sterne Journal: Int J Epidemiol Date: 2012-11-12 Impact factor: 7.196
Authors: Elizabeth C Russell; Salome Charalambous; Lindiwe Pemba; Gavin J Churchyard; Alison D Grant; Katherine Fielding Journal: BMC Public Health Date: 2010-07-23 Impact factor: 3.295
Authors: Margaret T May; Suzanne M Ingle; Dominique Costagliola; Amy C Justice; Frank de Wolf; Matthias Cavassini; Antonella D'Arminio Monforte; Jordi Casabona; Robert S Hogg; Amanda Mocroft; Fiona C Lampe; François Dabis; Gerd Fätkenheuer; Timothy R Sterling; Julia del Amo; M John Gill; Heidi M Crane; Michael S Saag; Jodie Guest; Hans-Reinhard Brodt; Jonathan A C Sterne Journal: Int J Epidemiol Date: 2013-04-18 Impact factor: 7.196
Authors: Kaku A So-Armah; Joyce Chang; Charles Alcorn; Vincent Lo Re; Jason V Baker; Russell Tracy; Adeel A Butt; Brian K Agan; David Rimland; Cynthia L Gibert; Matthew B Goetz; Krisann K Oursler; Maria C Rodriguez-Barradas; Lewis H Kuller; Sheldon T Brown; James H Stein; Melissa Skanderson; Amy C Justice; Matthew S Freiberg Journal: Curr HIV Res Date: 2014 Impact factor: 1.581
Authors: Amy C Justice; K A McGinnis; M Skanderson; C C Chang; C L Gibert; M B Goetz; D Rimland; M C Rodriguez-Barradas; K K Oursler; S T Brown; R S Braithwaite; M May; K E Covinsky; M S Roberts; S L Fultz; K J Bryant Journal: HIV Med Date: 2009-09-14 Impact factor: 3.180